Laddar...
Successful rechallenge of cetuximab following severe infusion-related reactions: a case report
Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is associated with a risk of infusion reactions, similar to other infusional agents. Although avoiding a rechallenge with cetuximab following a severe infusion reaction is preferable, this may not be an option if few oth...
Sparad:
| Huvudupphovsmän: | , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
AME Publishing Company
2014
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3937754/ https://ncbi.nlm.nih.gov/pubmed/24653637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2014.02.02 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|